Laura Soucek and his colleagues (Masso-Valles et al., 2020) suggested that MYC, MYCL and MYCN might be therapeutic targets for lung cancer and that elevated Myc levels were also associated with treatment resistance, there may be significant opportunities for the combination of Myc inhibitors with immunotherapies. Here, MYCN is linked to lung carcinoma.